Bristol-Myers Squibb Company BMYS.VI Stock
Bristol-Myers Squibb Company Price Chart
Bristol-Myers Squibb Company BMYS.VI Financial and Trading Overview
Bristol-Myers Squibb Company stock price | 45.77 EUR |
Previous Close | 59 EUR |
Open | 59 EUR |
Bid | 58.6 EUR x N/A |
Ask | 59.7 EUR x N/A |
Day's Range | 59 - 59 EUR |
52 Week Range | 59 - 80.73 EUR |
Volume | 0 EUR |
Avg. Volume | 0 EUR |
Market Cap | 123.95B EUR |
Beta (5Y Monthly) | 0.433098 |
PE Ratio (TTM) | 18.380062 |
EPS (TTM) | 3.59 EUR |
Forward Dividend & Yield | 2.07 (3.43%) |
Ex-Dividend Date | April 6, 2023 |
1y Target Est | N/A |
BMYS.VI Valuation Measures
Enterprise Value | 155.18B EUR |
Trailing P/E | 18.380062 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.703502 |
Price/Book (mrq) | 3.8933613 |
Enterprise Value/Revenue | 3.385 |
Enterprise Value/EBITDA | 7.91 |
Trading Information
Bristol-Myers Squibb Company Stock Price History
Beta (5Y Monthly) | 0.433098 |
52-Week Change | -15.97% |
S&P500 52-Week Change | 20.43% |
52 Week High | 80.73 EUR |
52 Week Low | 59 EUR |
50-Day Moving Average | 61.87 EUR |
200-Day Moving Average | 68 EUR |
BMYS.VI Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 2.1B |
Float | 2.1B |
Short Ratio | N/A |
% Held by Insiders | 0.071% |
% Held by Institutions | 78.61% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 2.22 |
Trailing Annual Dividend Yield | 3.76% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.6472 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 15.94% |
Operating Margin (ttm) | 20.79% |
Gross Margin | 78.46% |
EBITDA Margin | 42.78% |
Management Effectiveness
Return on Assets (ttm) | 6.03% |
Return on Equity (ttm) | 23.07% |
Income Statement
Revenue (ttm) | 45.85B EUR |
Revenue Per Share (ttm) | 21.64 EUR |
Quarterly Revenue Growth (yoy) | -2.70% |
Gross Profit (ttm) | 36.38B EUR |
EBITDA | 19.62B EUR |
Net Income Avi to Common (ttm) | 7.31B EUR |
Diluted EPS (ttm) | 3.21 |
Quarterly Earnings Growth (yoy) | 77.00% |
Balance Sheet
Total Cash (mrq) | 9.27B EUR |
Total Cash Per Share (mrq) | 4.41 EUR |
Total Debt (mrq) | 39.39B EUR |
Total Debt/Equity (mrq) | 123.52 EUR |
Current Ratio (mrq) | 1.419 |
Book Value Per Share (mrq) | 15.154 |
Cash Flow Statement
Operating Cash Flow (ttm) | 12.22B EUR |
Levered Free Cash Flow (ttm) | 12.6B EUR |
Profile of Bristol-Myers Squibb Company
Country | Austria |
State | NY |
City | New York |
Address | 430 East 29th Street |
ZIP | 10016 |
Phone | 212 546 4000 |
Website | https://www.bms.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 34300 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Q&A For Bristol-Myers Squibb Company Stock
What is a current BMYS.VI stock price?
Bristol-Myers Squibb Company BMYS.VI stock price today per share is 45.77 EUR.
How to purchase Bristol-Myers Squibb Company stock?
You can buy BMYS.VI shares on the Vienna exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bristol-Myers Squibb Company?
The stock symbol or ticker of Bristol-Myers Squibb Company is BMYS.VI.
Which industry does the Bristol-Myers Squibb Company company belong to?
The Bristol-Myers Squibb Company industry is Drug Manufacturers-General.
How many shares does Bristol-Myers Squibb Company have in circulation?
The max supply of Bristol-Myers Squibb Company shares is 2.03B.
What is Bristol-Myers Squibb Company Price to Earnings Ratio (PE Ratio)?
Bristol-Myers Squibb Company PE Ratio is 12.74791100 now.
What was Bristol-Myers Squibb Company earnings per share over the trailing 12 months (TTM)?
Bristol-Myers Squibb Company EPS is 3.59 EUR over the trailing 12 months.
Which sector does the Bristol-Myers Squibb Company company belong to?
The Bristol-Myers Squibb Company sector is Healthcare.